The Introduction and Clinical Application of Cell-Free Tumor DNA.

Abstract

Cell-free tumor DNA (ctDNA) is a kind of potential tumor biomarkers originated from cancer lesion in the circulating liquids. Liquid biopsy, as a minimally invasive or noninvasive manner, is a cutting-edge technology to detect ctDNA and other circulating biomarkers in the blood or other body fluids. ctDNA is mostly used for cancer patients to select targeted drugs in clinical application. In addition, ctDNA could also be applied to monitor tumor progression and recurrence. In conclusion, ctDNA is a very promising tumor biomarker for diagnosis and monitoring, which would increasingly become a routine clinical application in recent years.

• Authors: Jun Li, Renzhong Liu, Cuihong Huang, Shifu Chen, Mingyan Xu
• Journal: Methods in molecular biology (Clifton, N.J.) (Methods Mol Biol) Vol. 1754 Pg. 45-65 ( 2018) ISSN: 1940-6029 [Electronic] United States
• PMID: 29536437 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Biomarkers, Tumor
• Circulating Tumor DNA
• RNA, Messenger

Topics

• Antineoplastic Agents (therapeutic use)
• Biomarkers, Tumor (analysis)
• Circulating Tumor DNA (analysis, genetics)
• Exosomes (genetics, metabolism)
• High-Throughput Nucleotide Sequencing (instrumentation, methods)
• Humans
• Liquid Biopsy (instrumentation, methods)
• Molecular Targeted Therapy (methods)
• Mutation
• Neoplasm Recurrence, Local (diagnosis, drug therapy, pathology)
• Neoplasms (diagnosis, drug therapy, genetics, pathology)
• Neoplastic Cells, Circulating (metabolism, pathology)
• Patient Selection
• RNA, Messenger (analysis, genetics)
• Reverse Transcriptase Polymerase Chain Reaction (instrumentation, methods)
• Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization (instrumentation, methods)
• Treatment Outcome